Correlation between vascular endothelial growth factor expression and prognosis of gliomas: a Meta analysis
10.3760/cma.j.issn.1671-8925.2017.03.002
- VernacularTitle:VEGF的表达与神经胶质瘤预后相关性的Meta分析
- Author:
Yujie XU
1
;
Xiaoning LIU
;
Xiaoyang SUN
;
Lianshu DING
Author Information
1. 南京医科大学附属淮安第一医院神经外科
- Keywords:
Glioma;
Vascular endothelial growth factor;
Prognosis;
Meta analysis
- From:
Chinese Journal of Neuromedicine
2017;16(3):222-227
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the value of vascular endothelial growth factor (VEGF) expression in the prognosis of glioma patients.Methods PubMcd,EMbase,Cochrane Library,CNKI and Wanfang data were searched for collecting retrospective cohort studies on the correlation between VEGF expression and prognosis of glioma patients,and relevant articles were also retrieved from inception to June,2016.Two reviewers independently screened the literature,extracted the data,and evaluated the quality.Then Meta analysis was performed with RevMan5.3 software,and the publication bias of literature was evaluated by means of Begg's funnel plot and Egger's method.Results A total of 19 studies with 1657 cases were included.No significant publication bias was found in all groups.The analysis demonstrated positive associations between VEGF expression and poor prognosis (hazard ratio [HR]=1.39,95％CI:1.12-1.73),and the difference was statistically significant (P=0.003).Subgroup analysis showed that the high expression of VEGF in the European and American patients was more valuable than that in the Asian patients in the prognosis of gliomas;large samples of clinical studies of high VEGF expression were more valuable in the prognosis of gliomas than small samples.The detection of VEGF expression by different methods suggested that the patients with high expression of VEGF had poor prognosis;HR provided by the literature suggested that VEGF over-expression was associated with poor prognosis.Conclusion The expression of VEGF has predictive value for the survival time of glioma patients and VEGF can be recommended as a useful survival biomarker in clinical practice.
